Advanced PCR & NAAT Testing in Nepal — Molecular Diagnostics How Molecular Testing Works, What It Detects & Why the Specimen Matters

What PCR/NAAT Actually Is

PCR (polymerase chain reaction) and NAAT (nucleic acid amplification testing) are molecular methods that detect an organism's genetic material directly — amplifying tiny amounts of DNA or RNA until they are measurable. For infections where they apply, they are most sensitive and specific diagnostic tools available, detecting infection at organism levels far below what culture or microscopy can reach.

For STI diagnosis, NAAT is standard of care for chlamydia and gonorrhea — with sensitivity around ~95%+ when correct specimen is collected — and most reliable method for herpes from a fresh lesion. It is also method behind HIV RNA testing (early detection ~10–33 days) and viral load monitoring.

The critical, often-missed point: specimen determines what NAAT detects. A urine NAAT detects urethral infection but misses most throat and rectal infection — testing sites that were actually exposed, with right specimen from each, is what makes method accurate. The technology is only as good as what is fed to it.

What PCR/NAAT Detects

Chlamydia and gonorrhea — flagship NAAT targets — are detected with ~95%+ sensitivity and very high specificity on correct specimen (first-catch urine for urethral infection, swabs for cervical, throat and rectal sites). Trichomoniasis, mycoplasma and several other organisms are also detected by NAAT.

Herpes is best diagnosed by PCR on a swab from a fresh lesion (~2–12 days is productive window) — more reliable for acute diagnosis than serology. HIV RNA by NAAT detects infection earlier than antigen/antibody tests — the ~10–33 day window — and is method for viral load monitoring in diagnosed patients.

Why the Specimen Decides

NAAT is only as good as specimen it is given. A urine sample detects infection in urethra — but it does not detect infection in throat or rectum, which are sites that matter after oral or anal exposure. Roughly 85–90% of extragenital gonorrhea and a substantial fraction of extragenital chlamydia is missed by urine-only testing.

The consequence is practical: if exposure involved throat or rectum, those sites need their own swabs — not a urine test that cannot see them. Site-matched sampling is difference between a test that actually covers your exposure and one that silently misses infection it was meant to find.

Accuracy & Its Limits

NAAT is very accurate but not perfect: ~95%+ sensitivity for chlamydia/gonorrhea on correct specimen, high specificity, and known limit that window periods apply — testing too early after exposure can be negative even with a good test because organism has not yet reached detectable levels.

False results have causes: too-early testing, wrong specimen for exposure site, recent antibiotics partially suppressing organism, or collection issues. Where a result does not fit clinical picture — a symptomatic patient with a negative test, or an unexpected positive — retesting or supplementary testing is considered honestly rather than result taken at face value.

When Molecular Testing Is the Right Choice

NAAT is right choice when a sensitive, direct detection is needed for organisms it covers — chlamydia and gonorrhea diagnosis, lesion-PCR for acute herpes, early HIV RNA detection, and trichomoniasis or mycoplasma where indicated.

It is not answer for everything: syphilis is a serological diagnosis (blood tests), hepatitis is serological, and chronic HIV is monitored by antigen/antibody testing plus viral load. The correct test for infection — not always newest or most molecular option — is what an informed service chooses.

Molecular Testing & Costs

Transparent pricing; confirm turnaround when booking.

Related Services & Guides